HKD 3.49
(4.18%)
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2023 | 558.19 Million CNY | 27.84% |
2022 | 436.64 Million CNY | -86.9% |
2021 | 3.33 Billion CNY | 88.72% |
2020 | 1.76 Billion CNY | 0.0% |
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2024 Q2 | 490.66 Million CNY | 0.0% |
2024 Q1 | 490.66 Million CNY | -12.1% |
2023 Q3 | 558.19 Million CNY | 6.6% |
2023 FY | 558.19 Million CNY | 27.84% |
2023 Q1 | 523.66 Million CNY | 19.93% |
2023 Q2 | 523.66 Million CNY | 0.0% |
2023 Q4 | 558.19 Million CNY | 0.0% |
2022 Q3 | 436.64 Million CNY | 0.0% |
2022 Q4 | 436.64 Million CNY | 0.0% |
Name | Total Liabilities | Total Liabilities Difference |
---|---|---|
Uni-Bio Science Group Limited | 152.81 Million HKD | -265.269% |
CK Life Sciences Int'l., (Holdings) Inc. | 7.05 Billion HKD | 92.091% |